55 APOE4 carriers used red light therapy for 4months: This is what happened

Think about every prevention headline you’ve read. “Reduces risk by X%.” Buried underneath is a study run on people nothing like you, on a Tuesday afternoon, in a room you’ll never sit in. That’s not a knock on science. It’s a gap. On one side: the clinical trial, clean and controlled. On the other: you, with variable sleep, a wearable that sometimes doesn’t sync, supplements you remember most days, and months of messy, continuous, real data. Almost nobody studies that second world. We built a platform that lives in it, so we could.

Over four months (October 2025 to February 2026), a group of APOE4 carriers added one thing to their lives: a transcranial photobiomodulation device, a helmet that sends gentle near-infrared light into the brain. Then we measured everything around it. Six continuous streams per person: cognitive testing, sleep from Oura rings, blood biomarkers, HRV, daily check-ins, and device-usage logs. All captured inside one platform. The cohort was high-risk on purpose: APOE4 carriers, 64% of them homozygous (two copies, the highest genetic risk there is). These are exactly the people most prevention research never reaches. One honest note up front: different measures had different numbers of people, which is normal for real-world data. So judge each result against its own sample, not one headline number. We’ll tell you the sample every time.

Before the results, a promise: I’m going to give you the honest version, not the marketing version. The study was small. That matters. A small study can only reliably catch big changes, so when a result just misses the cutoff, it’s usually real and simply waiting on a bigger sample to confirm. Keep that in mind as you read. Three labels, that’s all you need: Significant (p < .05) — strong, trust it. Near-significant (p = .05–.11) — likely real, needs more people. Stable — no meaningful change.

Here’s the thing the helmet can’t give you. This study happened because thousands of APOE4 carriers decided to stop guessing and start measuring, together, in one place. 4,000+ carriers on Phoenix. 550+ actively running their own experiments. That’s the engine. That’s what turns a hunch into evidence. When you join Phoenix, you’re not on the outside reading the next result. You’re in it. Your bloodwork, your sleep, your cognition become part of the dataset that proves what actually works for our genotype, while you get APOE4-specific tracking, a community of carriers who get it, and early access to studies like this one. You carry APOE4. You can’t change that. But you can stop facing it alone, and start turning your own data into answers. 👉 Join Phoenix and get into the next study This is a movement, not a startup. Come build the evidence with us. Dr. Kevin Tran, Founder, Phoenix (APOE4/4) PS. Two ways forward, your choice. Want the device we studied? Code PHOENIX takes $100 off the LIGHT or the Neuradiant , with a 90-night trial so there’s nothing to lose. Want to help build the proof and get the tools for your own protocol? Join Phoenix. The carriers who do both tend to be the ones who, a year from now, actually know what’s working, instead of hoping. Education, not medical advice. Findings are observational, single-cohort, partly single-subject (n = 1), with no control group, and are not proof of efficacy. Neuronic devices are not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any device or protocol. Phoenix may earn an affiliate commission on Neuronic purchases; it does not influence our recommendations or the study data.